在患有转移性NCOA4::RET的患者中,对重新分化的持久反应是融合驱动的乳头甲状腺癌
Valentina D Tarasova1, Christine H Chung1, Sarimar Agosto Salgado1
1Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
JCEM case reports
|May 7, 2025
概括
再区分疗法与RET抑制剂相结合,有效治疗了放射性耐火性转移性甲状腺癌. 这种方法增强了放射性的吸收,导致持续的瘤反应和无进展的生存.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 放射学 放射学是一门学科.
背景情况:
- 重新分化疗法 (RDT) 对毛囊细胞衍生的甲状腺癌 (TC) 显示出前景.
- 关于研发与开发技术在核聚变驱动的TC的长期成果的数据有限.
- 放射性 (RAI) 耐火性转移性渐进型乳头TC是一个治疗挑战.
研究的目的:
- 评估RDT在患者的长期临床结果与融合驱动的TC.
- 评估选择性RET抑制剂与RDT结合的疗效.
- 调查RDT对转移性TC的RAI狂热的影响.
主要方法:
- 一名患有NCOA4::RET融合驱动的乳头TC的患者接受了selpercatinib (一种选择性RET抑制剂) 3个月.
- 在接受selpercatinib治疗后,该患者接受了治疗剂量的RAI (146mCi).
- 在24个月内,通过成像 (CT扫描) 和生化标志物 (铁血球蛋白水平) 评估了临床结果.
主要成果:
- 后RDT扫描显示在肺转移中增加了RAI热情.
- 甲状腺蛋白水平显著下降,肺结节完全消失.
- 患者在24个月后没有出现进展的迹象,甲状腺球蛋白水平继续下降.
- 在RAI治疗和停止selpercatinib治疗后的24个月内,持续的结构和生化反应得到维持.
结论:
- 与selpercatinib结合的RDT增强了融合驱动TC中的RAI吸收.
- 这种组合疗法在转移性疾病中实现了持久的结构和生化反应.
- 需要进一步的临床试验来探索使用选择性抑制剂在基因融合驱动的TC中的RDT.
相关概念视频
02:40Cancer Stem Cells and Tumor Maintenance
4.6K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.6K
02:30Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K